CVS Health Corp. (CVS) Stock Forecast
Data as of Oct 31, 2026Healthcare · Current price $90.12 (-0.20%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Mar 5, 2026 | Michael Cherny | Leerink Partners | $98.00 | +8.7% |
| Dec 10, 2025 | Ann Hynes | Mizuho Securities | $95.00 | +5.4% |
| Dec 10, 2025 | Jessica Tassan | Piper Sandler | $101.00 | +12.1% |
| Dec 10, 2025 | Kevin Caliendo | UBS | $97.00 | +7.6% |
| Oct 14, 2025 | David MacDonald | Truist Financial | $92.00 | +2.1% |
| Oct 14, 2025 | Erin Wright | Morgan Stanley | $89.00 | -1.2% |
| Oct 9, 2025 | Ann Hynes | Mizuho Securities | $88.00 | -2.4% |
| Sep 4, 2025 | Andrew Mok | Barclays | $87.00 | -3.5% |
| Aug 18, 2025 | Kevin Caliendo | UBS | $79.00 | -12.3% |
| Aug 14, 2025 | Michael Ha | Robert W. Baird | $82.00 | -9.0% |
| Jun 2, 2025 | Andrew Mok | Barclays | $79.00 | -12.3% |
| Dec 3, 2024 | George Hill | Deutsche Bank | $66.00 | -26.8% |
| Nov 18, 2024 | Stephen Baxter | Wells Fargo | $66.00 | -26.8% |
| Oct 24, 2024 | Ann Hynes | Mizuho Securities | $66.00 | -26.8% |
| Oct 21, 2024 | David MacDonald | Truist Financial | $76.00 | -15.7% |
| Oct 21, 2024 | Jessica Tassan | Piper Sandler | $72.00 | -20.1% |
| Oct 10, 2024 | Andrew Mok | Barclays | $82.00 | -9.0% |
| Aug 8, 2024 | George Hill | Deutsche Bank | $63.00 | -30.1% |
| Jun 28, 2024 | Lisa Gill | J.P. Morgan | $86.00 | -4.6% |
| Jun 28, 2024 | Brian Abrahams | RBC Capital | $74.00 | -17.9% |
Top Analysts Covering CVS
CVS vs Sector & Market
| Metric | CVS | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.00 | 2.25 | 2.41 |
| Analyst Count | 28 | 8 | 19 |
| Target Upside | +23.4% | +153002.0% | +21.5% |
| P/E Ratio | 39.70 | 3.43 | 38.49 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $394.56B | $404.39B | $417.43B | 18 |
| 2027-03-31 | $96.64B | $99.22B | $103.37B | 6 |
| 2027-06-30 | $101.62B | $104.33B | $108.69B | 6 |
| 2027-09-30 | $105.52B | $108.33B | $112.86B | 6 |
| 2027-12-31 | $108.67B | $111.57B | $116.23B | 6 |
| 2028-03-31 | $102.46B | $105.19B | $109.59B | 6 |
| 2028-06-30 | $107.29B | $110.15B | $114.76B | 5 |
| 2028-09-30 | $111.82B | $114.80B | $119.60B | 5 |
| 2028-12-31 | $115.33B | $118.41B | $123.36B | 6 |
| 2029-12-31 | $458.51B | $472.80B | $494.82B | 12 |
| 2030-12-31 | $479.11B | $494.04B | $517.06B | 6 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $7.07 | $7.16 | $7.35 | 18 |
| 2027-03-31 | $2.40 | $2.48 | $2.62 | 6 |
| 2027-06-30 | $2.02 | $2.09 | $2.20 | 6 |
| 2027-09-30 | $1.98 | $2.05 | $2.16 | 6 |
| 2027-12-31 | $1.58 | $1.63 | $1.72 | 6 |
| 2028-03-31 | $2.78 | $2.88 | $3.04 | 7 |
| 2028-06-30 | $2.37 | $2.45 | $2.58 | 7 |
| 2028-09-30 | $2.27 | $2.35 | $2.48 | 7 |
| 2028-12-31 | $1.81 | $1.87 | $1.97 | 7 |
| 2029-12-31 | $10.15 | $10.56 | $11.20 | 4 |
| 2030-12-31 | $11.15 | $11.61 | $12.31 | 4 |
Frequently Asked Questions
What is the analyst consensus for CVS?
The consensus among 28 analysts covering CVS Health Corp. (CVS) is Buy with an average price target of $111.20.
What is the highest price target for CVS?
The highest price target for CVS is $125.00, set by Ivan Feinseth at Tigress Financial on 2022-04-11.
What is the lowest price target for CVS?
The lowest price target for CVS is $63.00, set by George Hill at Deutsche Bank on 2024-08-08.
How many analysts cover CVS?
28 analysts have issued ratings for CVS Health Corp. in the past 12 months.
Is CVS a buy or sell right now?
Based on 28 analyst ratings, CVS has a consensus rating of Buy (2.00/5) with a +23.4% upside to the consensus target of $111.20.
What are the earnings estimates for CVS?
Analysts estimate CVS will report EPS of $7.16 for the period ending 2026-12-31, with revenue estimated at $404.39B.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.